Arete Wealth Advisors’s Biogen BIIB Stock Holding History

Arete Wealth Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-878	Closed	-$204K	–	721
2024 Q2	$204K	Buy	+878	New	+$191K	0.02%	659

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Arete Wealth Advisors's BIIB Position: Q3 2024 in Review

Arete Wealth Advisors sold out of Biogen (BIIB) in Q3 2024, closing a stake of 878 shares — an estimated $204K sold.

Arete Wealth Advisors first reported a position in BIIB in Q2 2024 and held it in 1 quarter. The position peaked at $204K in Q2 2024. 917 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

Arete Wealth Advisors reported no remaining Biogen position as of Q3 2024 after selling out during the quarter.
Arete Wealth Advisors sold 878 Biogen shares in Q3 2024, an estimated $204K.
Arete Wealth Advisors first reported a position in Biogen in Q2 2024 and held it in 1 quarter.
Arete Wealth Advisors's Biogen position peaked at $204K in Q2 2024.
917 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on Arete Wealth Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.